Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

PLRX

Pliant Therapeutics Inc

Nov 27 • 04:00PM ET

13.53

Dollar change +0.19
Percentage change 1.42	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX SRPT BMRN ALNY IONS BLUE ARWR RARE CRSP SGMO

| Held by: VTI IWM VXF IWN IBB VTWO SCHA VHT IHE XPH

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.34	Insider Own	11.67%	Shs Outstand	59.92M	Perf Week	6.28%
Market Cap	835.08M	Forward P/E	-	EPS next Y	-4.02	Insider Trans	-1.11%	Shs Float	53.75M	Perf Month	-8.08%
Income	-201.68M	PEG	-	EPS next Q	-0.99	Inst Own	96.17%	Short Float	13.57%	Perf Quarter	2.73%
Sales	0.00M	P/S	-	EPS this Y	-32.31%	Inst Trans	-1.56%	Short Ratio	17.41	Perf Half Y	11.18%
Book/sh	5.68	P/B	2.38	EPS next Y	-10.46%	ROA	-40.90%	Short Interest	7.29M	Perf Year	-4.45%
Cash/sh	6.55	P/C	2.06	EPS next 5Y	-	ROE	-47.52%	52W Range	10.22 - 19.62	Perf YTD	-25.29%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-22.68%	ROI	-49.71%	52W High	-31.04%	Beta	1.05
Dividend TTM	-	Quick Ratio	10.26	Sales past 5Y	-32.88%	Gross Margin	-1160.48%	52W Low	32.39%	ATR (14)	0.81
Dividend Ex-Date	-	Current Ratio	10.26	EPS Y/Y TTM	-20.25%	Oper. Margin	0.00%	RSI (14)	50.36	Volatility	5.15% 6.20%
Employees	158	Debt/Eq	0.17	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	40.18
Option/Short	Yes / Yes	LT Debt/Eq	0.17	EPS Q/Q	-36.83%	Payout	-	Rel Volume	0.80	Prev Close	13.34
Sales Surprise	-100.00%	EPS Surprise	1.98%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	418.73K	Price	13.53
SMA20	-1.69%	SMA50	2.67%	SMA200	1.63%	Trades		Volume	333,273	Change	1.42%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-24	Resumed	Leerink Partners	Outperform	$46 → $33
Dec-08-23	Initiated	Wells Fargo	Overweight	$41
May-18-23	Initiated	Canaccord Genuity	Buy	$48
Apr-13-23	Initiated	Robert W. Baird	Outperform	$44
Dec-14-22	Initiated	Stifel	Buy	$33
Dec-07-22	Initiated	JP Morgan	Overweight	$42
Sep-01-22	Initiated	Citigroup	Buy	$36
Jul-20-22	Initiated	SVB Leerink	Outperform	$33
May-25-22	Initiated	Cantor Fitzgerald	Overweight	$28
Dec-10-21	Initiated	Oppenheimer	Outperform	$40
Nov-24-21	Initiated	RBC Capital Mkts	Outperform	$38
Nov-03-21	Initiated	H.C. Wainwright	Buy	$45
Apr-20-21	Initiated	BTIG Research	Buy	$51
Apr-05-21	Initiated	Citigroup	Buy	$52
Jun-29-20	Initiated	Piper Sandler	Overweight	$50
Jun-29-20	Initiated	Needham	Buy	$40
Jun-29-20	Initiated	Cowen	Outperform
Jun-29-20	Initiated	Citigroup	Buy	$40

Show Previous Ratings

Nov-21-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Nov-18-24 06:00PM	Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting 2024 (GlobeNewswire)
Nov-07-24 04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-06-24 08:00AM	Pliant Therapeutics to Participate in the Stifel Healthcare Conference (GlobeNewswire) +5.37%
Oct-17-24 08:00AM	Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting 2024 (GlobeNewswire)
09:03PM	Loading…
Oct-04-24 09:03PM	Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc (GuruFocus.com)
Oct-01-24 04:35PM	Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs (GlobeNewswire) -5.89%
Sep-30-24 04:45PM	Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-24-24 08:00AM	Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer (GlobeNewswire)
Sep-10-24 08:00AM	Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024 (GlobeNewswire)
Aug-28-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-26-24 09:10AM	Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024 (GlobeNewswire)
Aug-07-24 11:53PM	PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q2 2024 (InvestorPlace)
04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
04:03PM	Loading…
Aug-06-24 04:03PM	Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Jul-15-24 08:00AM	Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures (GlobeNewswire)
Jun-24-24 12:56PM	7 Biotech Stocks to Buy on the Dip: June 2024 (InvestorPlace)
Jun-13-24 04:05PM	Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors (GlobeNewswire)
Jun-12-24 04:05PM	Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-24 08:00AM	Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress (GlobeNewswire)
May-21-24 06:50PM	Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference (GlobeNewswire)
May-14-24 11:28AM	Pliant Therapeutics Reports Positive Topline Data in Idiopathic Pulmonary Fibrosis Trial (MT Newswires)
07:30AM	Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis (GlobeNewswire)
May-07-24 08:35AM	Oppenheimer Adjusts Price Target on Pliant Therapeutics to $48 From $47, Maintains Outperform Rating (MT Newswires)
08:00AM	Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress (GlobeNewswire)
06:59AM	RBC Cuts Price Target on Pliant Therapeutics to $45 From $54, Keeps Outperform, Speculative Risk (MT Newswires)
May-06-24 09:55PM	PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-01-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire) +7.11%
08:00AM	Loading…
Apr-02-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Mar-27-24 10:23AM	Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference (GlobeNewswire)
Mar-12-24 07:30AM	Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Mar-07-24 10:00AM	Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline (Zacks)
Feb-27-24 04:03PM	Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results (GlobeNewswire)
Feb-26-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-07-24 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Feb-04-24 03:29PM	Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis (GlobeNewswire)
Jan-19-24 08:28PM	Pliant Therapeutics Inc CFO Keith Cummings Sells 9,781 Shares (GuruFocus.com) +5.57%
Jan-03-24 08:00AM	Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-13-23 04:30PM	Pliant Therapeutics Presentations at The Liver Meeting 2023 Highlight Bexotegrast, an Inhibitor of v 6 and v 1 Integrins, in Primary Sclerosing Cholangitis (GlobeNewswire) -7.09%
Nov-09-23 04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire) -5.52%
08:44AM	Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season? (Zacks)
Nov-08-23 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-23 10:00AM	Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Nov-06-23 08:00AM	Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins v 8 and v 1 (GlobeNewswire)
Oct-31-23 04:03PM	Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire) +5.16%
Oct-19-23 08:00AM	Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting 2023 (GlobeNewswire)
Oct-16-23 04:05PM	Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer (GlobeNewswire)
Sep-28-23 09:58AM	Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data (Zacks)
Sep-27-23 10:52AM	Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study (Zacks)
09:01AM	Pliant Therapeutics, Inc. (PLRX) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks)
Sep-26-23 02:26PM	Rebel's Edge - September 26: $IMVT, $PLRX, $UNFI, and The PAC12 (TheStreet.com) +14.33%
12:10PM	Why Shares of Pliant Therapeutics Are Rising Tuesday (Motley Fool)
07:30AM	Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis (GlobeNewswire)
Sep-25-23 04:05PM	Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis (GlobeNewswire)
Sep-15-23 08:00AM	Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer (GlobeNewswire)
Sep-11-23 08:00AM	Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023 (GlobeNewswire)
Aug-30-23 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-28-23 04:05PM	Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023 (GlobeNewswire)
10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Aug-09-23 05:15PM	Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:03PM	Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
08:00AM	Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Jul-25-23 08:00AM	Pliant Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-23-23 07:30AM	Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress (GlobeNewswire)
Jun-05-23 08:02PM	Over 100% Upside: Analysts See an Appealing Entry Point in These 2 Small-Cap Stocks (TipRanks)
06:19AM	Investors in Pliant Therapeutics (NASDAQ:PLRX) have seen splendid returns of 253% over the past year (Simply Wall St.)
May-24-23 08:00AM	Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference (GlobeNewswire)
May-18-23 01:50PM	Top Pharmaceutical Stocks for Q2 2023 (Investopedia)
May-10-23 08:05AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
May-09-23 05:45PM	Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:02PM	Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 06:25PM	Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -5.10%
Apr-30-23 02:10PM	Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures (GlobeNewswire)
Apr-12-23 08:01AM	Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference (GlobeNewswire)
Apr-09-23 01:19PM	7 Biotech Stocks to Buy for 100% Returns (InvestorPlace)
Mar-27-23 08:01AM	Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference (GlobeNewswire)
Mar-13-23 08:01AM	Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis (GlobeNewswire)
Mar-11-23 07:29AM	Pliant Therapeutics Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Mar-09-23 06:15PM	Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -9.01%
04:05PM	Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results (GlobeNewswire)
Mar-08-23 04:01PM	Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors (GlobeNewswire)
Mar-05-23 07:55AM	Pliant Therapeutics, Inc. (NASDAQ:PLRX) is a favorite amongst institutional investors who own 58% (Simply Wall St.)
Mar-01-23 08:01AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Feb-24-23 01:03PM	Novartis Takes Down $80M NASH Pact With Pliant Therapeutics (Benzinga)
Feb-07-23 08:01AM	Pliant Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Feb-02-23 08:02AM	Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors (GlobeNewswire)
07:45AM	Techne (TECH) Q2 Earnings and Revenues Miss Estimates (Zacks)
Jan-27-23 04:03PM	Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jan-26-23 04:16PM	Why Pliant Therapeutics Stock Is Skyrocketing This Week (Motley Fool)
Jan-25-23 10:21AM	Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why (Zacks) +5.19%
08:01AM	Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer (GlobeNewswire)
Jan-24-23 09:19PM	Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering (GlobeNewswire) +8.78%
Jan-23-23 04:11PM	An Unexpected Feat Just Sent Pliant Therapeutics Soaring 35% (Investor's Business Daily) +34.52%
04:01PM	Pliant Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
08:59AM	Benzinga's Talk of the Town: Top Social Trending Stories You Need To Know (Benzinga)
07:49AM	Pliant Therapeutics shares rally 75% (MarketWatch)
06:16AM	Pliant Therapeutics Stock Surges After Positive Data From Lead Program In Scarred Lung Disorder (Benzinga)

Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lefebvre Eric	Chief Medical Officer	Jul 10 '24	Sale	11.56	12,319	142,408	213,052	Jul 12 06:45 PM
Hull Hans	Chief Business Officer	Jul 10 '24	Sale	11.56	9,900	114,444	227,494	Jul 12 06:41 PM
Cummings Keith Lamont	Chief Financial Officer	Jul 10 '24	Sale	11.56	10,911	126,131	282,115	Jul 12 06:37 PM
Coulie Bernard	President and CEO	Jul 10 '24	Sale	11.56	38,710	447,488	482,936	Jul 12 06:22 PM
Ouimette Mike	General Counsel & Corp. Sec'y	Jul 10 '24	Sale	11.56	7,656	88,503	94,044	Jul 12 06:15 PM
Cummings Keith Lamont	Chief Financial Officer	May 02 '24	Option Exercise	2.08	21,000	43,680	271,713	May 06 06:02 AM
Cummings Keith Lamont	Chief Financial Officer	Jan 17 '24	Sale	17.23	9,781	168,527	194,605	Jan 19 05:19 PM
Hull Hans	Chief Business Officer	Jan 17 '24	Sale	17.23	9,786	168,613	185,069	Jan 19 05:19 PM
Coulie Bernard	President and CEO	Jan 17 '24	Sale	17.23	25,721	443,173	316,382	Jan 19 05:19 PM
Lefebvre Eric	Chief Medical Officer	Jan 17 '24	Sale	17.23	10,295	177,383	156,920	Jan 19 05:18 PM
Ouimette Mike	General Counsel & Corp. Sec'y	Jan 17 '24	Sale	17.23	5,197	89,544	55,246	Jan 19 05:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLRX

Pliant Therapeutics Inc

Upgrade your FINVIZ experience